Aldosterone antagonists (spironolactone, eplerenone) also known as “potassium sparing diuretics” block the action of aldosterone inhibiting the reuptake of sodium and water. Normally, when sodium ...

Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists have an important role in diabetic kidney disease and related ...

Purpose: The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart ...

Raised blood pressure remains the leading modifiable risk factor for cardiovascular disease and premature mortality worldwide ...

Bethesda, Md. (Sept. 19, 2011) – Roughly 5 million people in the United States live with heart failure, a condition in which the heart is unable to pump blood around the body effectively. The causes ...

Less than one-third of patients hospitalized for heart failure and participating in a quality improvement registry received a guideline-recommended treatment of heart failure, aldosterone antagonist ...

A study published today in JAMA (October 21) by Nancy M. Albert and colleagues, exploring aldosterone antagonist usage among US patients hospitalised with heart failure, found that only one-third of ...

More than two-thirds of patients hospitalized with serious heart failure aren't prescribed an aldosterone antagonist, a recommended therapy that increases the odds of survival. Aldosterone is a ...

In the absence of contraindications, an aldosterone antagonist should be offered to patients with NYHA class III or IV heart failure and to patients after an MI with left ventricular dysfunction.